AAN-I-IFNs in longitudinal samples, as determined with the luciferase-based neutralization assay in P2 and P6 samples. (A–C) Plasma samples were diluted 1:10 and incubated with 10 ng/ml (A), 1 ng/ml (B), or 100 pg/ml (C) IFNs. Plasma samples from the APS-1 patients and the healthy donor were not longitudinal and were only used as control for type I IFNs neutralization. APS-1, autoimmune polyendocrinopathy syndrome type 1.